Skip Navigation

European Heart Journal 2003 24(24):2164-2165; doi:10.1016/j.ehj.2003.10.016
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wollert, K. C
Right arrow Articles by Drexler, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wollert, K. C
Right arrow Articles by Drexler, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Growth hormone and proinflammatory cytokine activation in heart failure

Just a new verse to an old sirens’ song?

Kai C Wollert and Helmut Drexler*

Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany

* Corresponding author: Prof. H. Drexler, Abt. Kardiologie und Angiologie Med. Hochschule Hannover, Carl-Neuberg Str. 1, 30625 Hannover, Germany. Tel.: +49-511-532-3840; Fax: +49-511-532-5412
E-mail address: drexler.helmut@mh-hannover.de

Received 9 October 2003; accepted 23 October 2003

The first 10% of the full text of this article appears below.

See doi:10.1016/S1095-668X(03)00480-9for thearticle to which this editorial refers

Despite recent advances in pharmacotherapy, patients living with heart failure carry a heavy burden in terms of morbidity and mortality. For example, in a recently completed large-scale clinical trial, 30% of patients with stable NYHA class II or III heart failure died during a mean follow-up period of less than 3 1/2 years; at the same time, 25% of these patients were hospitalized at least . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy
Stamatis Adamopoulos, John T. Parissis, Ioannis Paraskevaidis, Dimitrios Karatzas, Efthimios Livanis, Michael Georgiadis, George Karavolias, Dimitrios Mitropoulos, Dimitrios Degiannis, and Dimitrios Th. Kremastinos
EHJ 2003 24: 2186-2196. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 BioinformaticsHome page
G. Gamberoni, E. Lamma, G. Lodo, J. Marchesini, N. Mascellani, S. Rossi, S. Storari, L. Tagliavini, and S. Volinia
Fun&Co: identification of key functional differences in transcriptomes
Bioinformatics, October 15, 2007; 23(20): 2725 - 2732.
[Abstract] [Full Text] [PDF]